Engineered NK Cell Therapy for Liver Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for primary liver tumors, such as hepatocellular carcinoma, face challenges due to limited infiltration of natural killer (NK) cells into the tumor microenvironment, leading to suboptimal therapeutic efficacy and potential off-target toxicities.
Innovation Solution
Local administration of NK cells engineered to express a cytotoxic receptor complex, such as a chimeric NKG2D receptor, combined with anti-cancer agents like sorafenib, enhances tumor cell killing by improving NK cell sensitivity to NKG2D ligands and overcoming tumor microenvironment suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells are administered systemically to treat primary liver tumors, then tumor cell killing is enhanced through engagement of NKG2D receptor-ligand interactions, but off-target toxicities occur due to lack of selective accumulation in the tumor microenvironment
Solution Approach 1:
The patent applies local quality by engineering NK cells to express a chimeric NKG2D receptor that specifically targets NKG2D ligands overexpressed on liver tumor cells. This creates localized cytotoxic activity at the tumor site while sparing healthy tissues, resolving the contradiction between enhancing tumor cell killing and reducing off-target toxicities through selective receptor-ligand engagement in the liver tumor microenvironment
2Reliability
If NK cells are administered to treat hepatocellular carcinoma, then anti-tumor immunity is activated, but therapeutic efficacy is limited due to poor infiltration of NK cells into the tumor microenvironment
Solution Approach 1:
The patent uses the chimeric NKG2D receptor as an intermediary that bridges NK cells and liver tumor cells. The engineered receptor has enhanced affinity for NKG2D ligands, acting as a mediator that enables effective NK cell recognition and infiltration of the tumor microenvironment, thereby resolving the contradiction between activating anti-tumor immunity and achieving sufficient tumor penetration
3Ease of operation
If conventional NK cell therapy is used for primary liver tumors, then treatment simplicity is maintained, but therapeutic outcome is suboptimal due to tumor microenvironment suppression of NK cell function
Solution Approach 1:
The patent applies parameter changes by modifying the NK cell receptor parameters through genetic engineering. The chimeric NKG2D receptor incorporates a modified extracellular domain with enhanced binding affinity for NKG2D ligands, changing the functional parameters of NK cell recognition and cytotoxicity. This resolves the contradiction between treatment simplicity and therapeutic outcome by enhancing receptor function at the molecular level while maintaining the overall simplicity of adoptive cell therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered NK cells demonstrate enhanced cytotoxicity and tumor burden reduction, achieving at least a 25% decrease in hepatocellular carcinoma burden with reduced off-target effects through targeted intra-hepatic delivery.
Implementation Method 1
NK cells bearing engineered receptors, such as a CAR or chimeric receptor as disclosed herein bind to an NK ligand on a tumor cell. Cytotoxic signals are then generated which result in killing of tumor cells.
Data Source
AI summary
Several embodiments disclosed herein relate to the treatment of a tumor using immunotherapy. Several embodiments relate to the treatment of a liver tumor, such as hepatocellular carcinoma or a metastasis from another tumor location. Additional embodiments relate to combination therapies that employ Natural Killer (NK) cells engineered to express cytotoxic receptor complexes and additional anti-cancer agents to treat tumors.